Roxadustat for anemia in patients with end-stage renal disease incident to dialysis
R Provenzano, E Shutov, L Eremeeva… - Nephrology Dialysis …, 2021 - academic.oup.com
Background We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the
treatment of chronic kidney disease-related anemia in patients new to dialysis. Methods …
treatment of chronic kidney disease-related anemia in patients new to dialysis. Methods …
Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study
S Fishbane, CA Pollock, M El-Shahawy… - Journal of the …, 2022 - journals.lww.com
Background Concerns regarding cardiovascular safety with current treatments for anemia in
patients with dialysis-dependent (DD)-CKD have encouraged the development of …
patients with dialysis-dependent (DD)-CKD have encouraged the development of …
[HTML][HTML] Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6-to 19-week, open-label …
R Provenzano, A Besarab, S Wright, S Dua… - American Journal of …, 2016 - Elsevier
Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl-hydroxylase
inhibitor that promotes erythropoiesis through increasing endogenous erythropoietin …
inhibitor that promotes erythropoiesis through increasing endogenous erythropoietin …
[HTML][HTML] Roxadustat treatment for anemia in patients undergoing long-term dialysis
N Chen, C Hao, BC Liu, H Lin, C Wang… - … England Journal of …, 2019 - Mass Medical Soc
Background Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and regulates iron metabolism. Additional data are needed …
stimulates erythropoiesis and regulates iron metabolism. Additional data are needed …
[HTML][HTML] A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study
C Charytan, R Manllo-Karim, ER Martin, D Steer… - Kidney international …, 2021 - Elsevier
Introduction Erythropoiesis-stimulating agents, standard of care for anemia of end-stage
kidney disease, are associated with cardiovascular events. We evaluated the efficacy and …
kidney disease, are associated with cardiovascular events. We evaluated the efficacy and …
Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active …
B Csiky, M Schömig, C Esposito, J Barratt, M Reusch… - Advances in …, 2021 - Springer
Introduction Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This …
inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This …
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)
E Shutov, W Sułowicz, C Esposito… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
[HTML][HTML] Roxadustat for anemia in patients with kidney disease not receiving dialysis
N Chen, C Hao, X Peng, H Lin, A Yin… - … England Journal of …, 2019 - Mass Medical Soc
Abstract Background Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor
(HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In …
(HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In …
Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and …
J Liu, A Zhang, JC Hayden, AS Bhagavathula… - Pharmacological …, 2020 - Elsevier
The effect of roxadustat (FG-4592) on individuals with chronic kidney diseases (CKD)
patients receiving or not receiving the dialysis was unclear. The aim of this study was to …
patients receiving or not receiving the dialysis was unclear. The aim of this study was to …
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)
J Barratt, B Andric, A Tataradze… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD) …
inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD) …